Andi Alfian Zainuddin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andi Alfian Zainuddin has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Pendrik Tandean
Hasanuddin University, Makassar, South Sulawesi, Indonesia
3 shared publications - Akhtar Fajar Muzakkir
Department of Cardiology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
2 shared publications - Abdul Hakim Alkatiri
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Hasanuddin, Makassar 90245, Indonesia
1 shared publication - Adhariana Kaddas
Department of Pediatrics, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
1 shared publication Advendila Margaretha Artz
1 shared publication- Aminuddin Aminuddin
Department of Clinical Nutrition, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
1 shared publication
Latest Publications
- Open Access
- 11 August 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, e200901
Astaxanthin supplementation is associated with a reduction in serum myeloperoxidase levels in subjects with abdominal obesity
Background : Central obesity is a condition characterized by increased abdominal adipose tissue and an increased risk of developing cardiometabolic diseases. In subjects with obesity, elevated myeloperoxidase (MPO) levels are observed because of the infiltration of polymorphonuclear leukocytes into adipose tissue, leading to increased oxidative stress. This study aimed to assess the effect of astaxanthin supplementation, a compound with strong antioxidant properties, on serum MPO levels in adult subjects with central obesity. Methods : This study is a quasi-experimental study with an open-label, prospective design. A total of 42 subjects with abdominal obesity participated in the study, including 21 subjects who received 4 mg of astaxanthin supplementation per day for 4 weeks and 21 control subjects who did not receive supplementation. Serum MPO levels were measured using an enzyme-linked immunosorbent assay (ELISA) before and after the intervention. Results : There was a significant difference in MPO levels before and after treatment among subjects with central obesity who received astaxanthin (median 20.30 [16.16] vs. 17.29 [10.23] pg/mL; p = 0.014), whereas there was no difference in MPO levels before and after the study period among subjects in the control group (median 19.94 [7.17] vs. 17.49 [9.14] pg/mL; p = 0.876). Conclusion : Supplementation with 4 mg of astaxanthin for 4 weeks reduces serum MPO levels in adult subjects with central obesity.
- 11 August 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73, e200901
Open AccessAstaxanthin supplementation is associated with a reduction in serum myeloperoxidase levels in subjects with abdominal obesity
Background : Central obesity is a condition characterized by increased abdominal adipose tissue and an increased risk of developing cardiometabolic diseases. In subjects with obesity, elevated myeloperoxidase (MPO) levels are observed because of the infiltration of polymorphonuclear leukocytes into adipose tissue, leading to increased oxidative stress. This study aimed to assess the effect of astaxanthin supplementation, a compound with strong antioxidant properties, on serum MPO levels in adult subjects with central obesity. Methods : This study is a quasi-experimental study with an open-label, prospective design. A total of 42 subjects with abdominal obesity participated in the study, including 21 subjects who received 4 mg of astaxanthin supplementation per day for 4 weeks and 21 control subjects who did not receive supplementation. Serum MPO levels were measured using an enzyme-linked immunosorbent assay (ELISA) before and after the intervention. Results : There was a significant difference in MPO levels before and after treatment among subjects with central obesity who received astaxanthin (median 20.30 [16.16] vs. 17.29 [10.23] pg/mL; p = 0.014), whereas there was no difference in MPO levels before and after the study period among subjects in the control group (median 19.94 [7.17] vs. 17.49 [9.14] pg/mL; p = 0.876). Conclusion : Supplementation with 4 mg of astaxanthin for 4 weeks reduces serum MPO levels in adult subjects with central obesity.
- Open Access
- 2 July 2026
- Published by JURUFRA SL in Retos
- Vol. 80, 835-846
Core stabilization with biofeedback-guided quadriceps–hamstring strengthening in knee osteoarthritis: a randomized trial
Introduction: Appropriate exercise therapies are still being investigated for primary knee osteoarthritis, which greatly contributes to chronic pain and functional impairment in older adults. Objective: The purpose of this study was to evaluate the effectiveness of adding core stability to biofeedback-assisted quadriceps-hamstring strengthening for individuals with primary osteoarthritis of the knee. Methodology: Participants between the ages of 50 and 65 participated in a parallel-group, randomised controlled study conducted at a single location. For six weeks, participants participated in twice-weekly supervised exercise sessions. The Western Ontario and McMaster Universities Osteoarthritis Index was used to assess functional status at baseline and on a weekly basis, while the Numeric Rating Scale was used to measure the intensity of pain. Results: Forty participants were randomized, with 39 completing the study. Both groups shown gradual enhancements in pain and functionality. Significant between-group differences in pain emerged from week four, and by week six, the combined intervention group showed lower pain levels compared to the strengthening-only group. Functional outcomes also showed significant differences at week six, favoring the combined intervention. Statistical analysis revealed significant time-by-group interactions for both pain and functional measures. Discussion: The addition of core stabilization appears to enhance the effectiveness of strengthening exercises, possibly by improving neuromuscular control and joint stability. Conclusions: Incorporating core stabilization into strengthening programs provides additional short-term benefits in reducing pain and improving function in individuals with primary knee osteoarthritis.
- 2 July 2026
- Published by JURUFRA SL in Retos
- Vol. 80, 835-846
Open AccessCore stabilization with biofeedback-guided quadriceps–hamstring strengthening in knee osteoarthritis: a randomized trial
Introduction: Appropriate exercise therapies are still being investigated for primary knee osteoarthritis, which greatly contributes to chronic pain and functional impairment in older adults. Objective: The purpose of this study was to evaluate the effectiveness of adding core stability to biofeedback-assisted quadriceps-hamstring strengthening for individuals with primary osteoarthritis of the knee. Methodology: Participants between the ages of 50 and 65 participated in a parallel-group, randomised controlled study conducted at a single location. For six weeks, participants participated in twice-weekly supervised exercise sessions. The Western Ontario and McMaster Universities Osteoarthritis Index was used to assess functional status at baseline and on a weekly basis, while the Numeric Rating Scale was used to measure the intensity of pain. Results: Forty participants were randomized, with 39 completing the study. Both groups shown gradual enhancements in pain and functionality. Significant between-group differences in pain emerged from week four, and by week six, the combined intervention group showed lower pain levels compared to the strengthening-only group. Functional outcomes also showed significant differences at week six, favoring the combined intervention. Statistical analysis revealed significant time-by-group interactions for both pain and functional measures. Discussion: The addition of core stabilization appears to enhance the effectiveness of strengthening exercises, possibly by improving neuromuscular control and joint stability. Conclusions: Incorporating core stabilization into strengthening programs provides additional short-term benefits in reducing pain and improving function in individuals with primary knee osteoarthritis.
- Open Access
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
Association Between Glycemic Variability Indices and Clinical Outcomes in Patients Without Diabetes Presenting with ST-Segment Elevation Myocardial Infarction: A Prospective Cohort Study
Introduction. Glycemic variability (GV) has emerged as a potential prognostic marker in acute cardiovascular conditions. While its association with adverse outcomes has been widely studied in diabetic populations, limited data exist regarding its clinical impact in non-diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI). Aim. This study aimed to evaluate the association between glycemic variability indices and short-term clinical outcomes in non-diabetic patients with STEMI. Materials and Methods. This prospective cohort study included 133 non-diabetic patients with STEMI admitted to a tertiary cardiac center. Blood glucose levels were measured serially during the first five days of hospitalization. Glycemic variability was assessed using the coefficient of variation (CoV), with a median cut-off value of 13.2 % used to categorize patients into low and high GV groups. Clinical outcomes, including mortality, heart failure, recurrent angina, and stroke, were assessed during hospitalization and up to 30 days to three months after discharge. Statistical analysis was performed using bivariate tests, with p<0.05 considered statistically significant. Results. The median age of participants was 60 years, and 78.2 % were male. Mortality occurred in 13.5 % of patients, heart failure in 74.4 %, recurrent angina in 30.1 %, and stroke in 8.3 %. No statistically significant associations were found between high GV (CoV≥13.2 %) and mortality (p=0.327), heart failure (p=0.959), recurrent angina (p=0.955), or stroke (p=0.110). Conclusions. In non-diabetic patients with STEMI, glycemic variability assessed during the acute hospitalization period was not significantly associated with short-term adverse clinical outcomes. These findings suggest that moderate glucose fluctuations in this population may not independently predict early complications.
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
Open AccessAssociation Between Glycemic Variability Indices and Clinical Outcomes in Patients Without Diabetes Presenting with ST-Segment Elevation Myocardial Infarction: A Prospective Cohort Study
Introduction. Glycemic variability (GV) has emerged as a potential prognostic marker in acute cardiovascular conditions. While its association with adverse outcomes has been widely studied in diabetic populations, limited data exist regarding its clinical impact in non-diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI). Aim. This study aimed to evaluate the association between glycemic variability indices and short-term clinical outcomes in non-diabetic patients with STEMI. Materials and Methods. This prospective cohort study included 133 non-diabetic patients with STEMI admitted to a tertiary cardiac center. Blood glucose levels were measured serially during the first five days of hospitalization. Glycemic variability was assessed using the coefficient of variation (CoV), with a median cut-off value of 13.2 % used to categorize patients into low and high GV groups. Clinical outcomes, including mortality, heart failure, recurrent angina, and stroke, were assessed during hospitalization and up to 30 days to three months after discharge. Statistical analysis was performed using bivariate tests, with p<0.05 considered statistically significant. Results. The median age of participants was 60 years, and 78.2 % were male. Mortality occurred in 13.5 % of patients, heart failure in 74.4 %, recurrent angina in 30.1 %, and stroke in 8.3 %. No statistically significant associations were found between high GV (CoV≥13.2 %) and mortality (p=0.327), heart failure (p=0.959), recurrent angina (p=0.955), or stroke (p=0.110). Conclusions. In non-diabetic patients with STEMI, glycemic variability assessed during the acute hospitalization period was not significantly associated with short-term adverse clinical outcomes. These findings suggest that moderate glucose fluctuations in this population may not independently predict early complications.
- Open Access
- 27 February 2026
- Published by Indygo Zahir Media in Aesthetic Cosmetology and Medicine
- Vol. 15 (1) , 11-18
The application of melatonin in anti-aging cosmetics. An overview of clinical efficacy and mechanisms of action
Skin changes associated with aging processes are increasingly recognized as a significant dermatological and aesthetic problems. Melatonin is an endogenous hormone known for its powerful antioxidant and anti-inflammatory properties. Its topical application is gaining popularity as an effective way to slow down the aging process. The study aimed to assess the potential effectiveness and mechanisms of action of melatonin as an anti-aging agent in cosmetics. A systematic review of studies was conducted on publications from January 1990 to April 2025 using the PRISMA guidelines, PubMed, ScienceDirect, Google Scholar, and Cochrane Library databases. Melatonin in cosmetic preparations has been shown to reduce wrinkles, improve skin firmness, and increase hydration. This was associated with the role of melatonin as a powerful antioxidant that reduces oxidative stress, improves mitochondrial function, regulates lipid metabolism, and protects collagen and elastin fibers, preventing skin damage and promoting skin rejuvenation. Topical application of melatonin appears promising, but further clinical studies are needed to confirm its efficacy and optimize formulation strategies.
- 27 February 2026
- Published by Indygo Zahir Media in Aesthetic Cosmetology and Medicine
- Vol. 15 (1) , 11-18
Open AccessThe application of melatonin in anti-aging cosmetics. An overview of clinical efficacy and mechanisms of action
Skin changes associated with aging processes are increasingly recognized as a significant dermatological and aesthetic problems. Melatonin is an endogenous hormone known for its powerful antioxidant and anti-inflammatory properties. Its topical application is gaining popularity as an effective way to slow down the aging process. The study aimed to assess the potential effectiveness and mechanisms of action of melatonin as an anti-aging agent in cosmetics. A systematic review of studies was conducted on publications from January 1990 to April 2025 using the PRISMA guidelines, PubMed, ScienceDirect, Google Scholar, and Cochrane Library databases. Melatonin in cosmetic preparations has been shown to reduce wrinkles, improve skin firmness, and increase hydration. This was associated with the role of melatonin as a powerful antioxidant that reduces oxidative stress, improves mitochondrial function, regulates lipid metabolism, and protects collagen and elastin fibers, preventing skin damage and promoting skin rejuvenation. Topical application of melatonin appears promising, but further clinical studies are needed to confirm its efficacy and optimize formulation strategies.
- Open Access
- 1 January 2026
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 29 (6) , 421-433
Clinical Benefits and Safety of Triple-Strain Bifidobacterium Supplementation for Preterm Infants in a Neonatal Intensive Care Unit Setting: A Hospital-Based Clinical Study in Indonesia
Kaddas A, et al. Pediatr Gastroenterol Hepatol Nutr. 2026 Nov;29(6):421-433. https://doi.org/10.5223/pghn.2026.29.6.421
- 1 January 2026
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 29 (6) , 421-433
Open AccessClinical Benefits and Safety of Triple-Strain Bifidobacterium Supplementation for Preterm Infants in a Neonatal Intensive Care Unit Setting: A Hospital-Based Clinical Study in Indonesia
Kaddas A, et al. Pediatr Gastroenterol Hepatol Nutr. 2026 Nov;29(6):421-433. https://doi.org/10.5223/pghn.2026.29.6.421
- Open Access
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4) , 147-155
Effect of Macrolide and Non-Macrolide Therapy on QTc Interval Prolongation in Cardiac Patients with Community-Acquired Pneumonia
Introduction. Azithromycin is a macrolide antibiotic widely used to treat various infectious diseases, such as respiratory infections. Several studies have reported an association between azithromycin and QT interval prolongation. QTc prolongation is one of the causes of the life-threatening arrhythmia torsade de pointes (TdP). Torsade de pointes has been reported in approximately 1 % of patients with QT interval prolongation after exposure to azithromycin. Aim. This study aims to determine the effect of macrolide and non-macrolide regimen therapy on the prolongation of the QTc interval in cardiac patients with community-acquired pneumonia. Materials and Methods. This is a retrospective cohort study of 33 cardiac patients with community-acquired pneumonia who received macrolide and non-macrolide therapy during hospitalization. Serial electrocardiograms were performed on days 1, 3, 5, and pre-discharge to evaluate the QTc interval. Outcomes. In the group of heart disease patients with community-acquired pneumonia who received macrolides, there was a significant prolongation of the QTc interval (p<0.05) in the independent T-test, Mann-Whitney test, and Friedman test. Risk factors of age, female gender, history of hypertension, and diabetes mellitus had a significant effect (p<0.05) in the Friedman test. Conclusions. This study shows that macrolide therapy in heart disease patients with community-acquired pneumonia significantly and consistently prolongs the QTc interval throughout the treatment period compared with non-macrolide therapy. Risk factors include age, female gender, history of hypertension, and diabetes mellitus.
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4) , 147-155
Open AccessEffect of Macrolide and Non-Macrolide Therapy on QTc Interval Prolongation in Cardiac Patients with Community-Acquired Pneumonia
Introduction. Azithromycin is a macrolide antibiotic widely used to treat various infectious diseases, such as respiratory infections. Several studies have reported an association between azithromycin and QT interval prolongation. QTc prolongation is one of the causes of the life-threatening arrhythmia torsade de pointes (TdP). Torsade de pointes has been reported in approximately 1 % of patients with QT interval prolongation after exposure to azithromycin. Aim. This study aims to determine the effect of macrolide and non-macrolide regimen therapy on the prolongation of the QTc interval in cardiac patients with community-acquired pneumonia. Materials and Methods. This is a retrospective cohort study of 33 cardiac patients with community-acquired pneumonia who received macrolide and non-macrolide therapy during hospitalization. Serial electrocardiograms were performed on days 1, 3, 5, and pre-discharge to evaluate the QTc interval. Outcomes. In the group of heart disease patients with community-acquired pneumonia who received macrolides, there was a significant prolongation of the QTc interval (p<0.05) in the independent T-test, Mann-Whitney test, and Friedman test. Risk factors of age, female gender, history of hypertension, and diabetes mellitus had a significant effect (p<0.05) in the Friedman test. Conclusions. This study shows that macrolide therapy in heart disease patients with community-acquired pneumonia significantly and consistently prolongs the QTc interval throughout the treatment period compared with non-macrolide therapy. Risk factors include age, female gender, history of hypertension, and diabetes mellitus.
- Open Access
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4)
Comparative Effects of 12 Weeks of Center-Based versus Home-Based Exercise Training on hs-CRP and IL-6 Levels in Patients with Heart Failure Reduced Ejection Fraction
Introduction. Heart failure (HF) is a global health concern characterized by significant morbidity and mortality, often associated with chronic systemic inflammation. Exercise-based cardiac rehabilitation is a cornerstone of HF management; however, accessibility limitations often restrict participation. Home-based exercise programs offer a potentially viable alternative. This study aimed to evaluate the effects of 12 weeks of center-based versus home-based exercise training on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), in patients with heart failure with reduced ejection fraction. Aim. This study aimed to evaluate the effects of 12 weeks of center-based versus home-based exercise training on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), in patients with heart failure reduced ejection fraction. Materials and Methods. A quasi-experimental design was employed involving 31 patients diagnosed with heart failure with left ventricular ejection fraction below 40 %. Participants were allocated into two groups: center-based exercise (n=15) and home-based exercise (n=16). Both groups underwent a 12-week exercise rehabilitation program consisting of light-intensity sessions five times per week. Baseline and post-intervention blood samples were collected to measure serum levels of hs-CRP and IL-6. Clinical and demographic data were also recorded. Statistical analyses were performed using the Mann–Whitney and Wilcoxon signed-rank tests, with significance set at p<0.05. Results and Discussion. Both exercise modalities resulted in significant reductions in IL-6 and hs-CRP levels after 12 weeks (p<0.001). Median IL-6 decreased from 13.1 pg/mL to 4.8 pg/mL, while median hs-CRP declined from 4.3 mg/L to 2.5 mg/L across all participants. No statistically significant differences were observed between the center-based and home-based groups in the extent of reduction for either biomarker (IL-6, p=0.906; hs-CRP, p=0.200). Conclusions. Twelve weeks of home-based exercise training is as effective as center-based training in reducing systemic inflammation, as measured by IL-6 and hs-CRP, in patients with heart failure with reduced ejection fraction. These findings support the use of home-based rehabilitation as a viable alternative to center-based programs for managing inflammation in this patient population.
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4)
Open AccessComparative Effects of 12 Weeks of Center-Based versus Home-Based Exercise Training on hs-CRP and IL-6 Levels in Patients with Heart Failure Reduced Ejection Fraction
Introduction. Heart failure (HF) is a global health concern characterized by significant morbidity and mortality, often associated with chronic systemic inflammation. Exercise-based cardiac rehabilitation is a cornerstone of HF management; however, accessibility limitations often restrict participation. Home-based exercise programs offer a potentially viable alternative. This study aimed to evaluate the effects of 12 weeks of center-based versus home-based exercise training on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), in patients with heart failure with reduced ejection fraction. Aim. This study aimed to evaluate the effects of 12 weeks of center-based versus home-based exercise training on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), in patients with heart failure reduced ejection fraction. Materials and Methods. A quasi-experimental design was employed involving 31 patients diagnosed with heart failure with left ventricular ejection fraction below 40 %. Participants were allocated into two groups: center-based exercise (n=15) and home-based exercise (n=16). Both groups underwent a 12-week exercise rehabilitation program consisting of light-intensity sessions five times per week. Baseline and post-intervention blood samples were collected to measure serum levels of hs-CRP and IL-6. Clinical and demographic data were also recorded. Statistical analyses were performed using the Mann–Whitney and Wilcoxon signed-rank tests, with significance set at p<0.05. Results and Discussion. Both exercise modalities resulted in significant reductions in IL-6 and hs-CRP levels after 12 weeks (p<0.001). Median IL-6 decreased from 13.1 pg/mL to 4.8 pg/mL, while median hs-CRP declined from 4.3 mg/L to 2.5 mg/L across all participants. No statistically significant differences were observed between the center-based and home-based groups in the extent of reduction for either biomarker (IL-6, p=0.906; hs-CRP, p=0.200). Conclusions. Twelve weeks of home-based exercise training is as effective as center-based training in reducing systemic inflammation, as measured by IL-6 and hs-CRP, in patients with heart failure with reduced ejection fraction. These findings support the use of home-based rehabilitation as a viable alternative to center-based programs for managing inflammation in this patient population.
- Open Access
- 4 December 2025
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(88),p. 39-44
Prospective case series on home-based handgrip resistance training with WhatsApp monitoring in patients with newly created arteriovenous fistulas
Successful maturation of arteriovenous fistulas (AVFs) remains a challenge for patients with end-stage kidney disease, particularly in resource-limited settings. Handgrip resistance training may enhance vascular hemodynamics and support AVF maturation. This prospective uncontrolled case series evaluated the feasibility, safety, and vascular changes of a four-week home-based handgrip program in patients with new AVFs. Methods. Twenty-eight adults with recent radiocephalic AVF creation performed daily handgrip training for four weeks (three sets of 10 contractions, 10 seconds each with 2-second rests; ~3–5 minutes/day). Adherence was tracked via logbooks and weekly WhatsApp submissions. Feasibility outcomes included adherence, completion, safety, and patient acceptability. Hemodynamic parameters (vein diameter, vein depth, and blood flow volume) were measured using Doppler ultrasonography before and after the intervention. Results. Of 28 participants, 23 (82.1%) completed the program with high adherence (≥85% sessions). No AVF-related adverse events occurred. Significant vascular changes were observed: vein diameter increased from 3.1 ± 0.4 mm to 5.5 ± 0.6 mm (p < 0.001), vein depth decreased from 2.5 ± 0.3 mm to 2.1 ± 0.4 mm (p = 0.002), and blood-flow volume increased from 180 ± 55 mL/min to 565 ± 110 mL/min (p < 0.001). Conclusions. Home-based handgrip training with digital monitoring is feasible, safe, and well accepted in patients with new AVFs. The observed vascular changes suggest this low-cost intervention may support AVF maturation and is suitable for integration into dialysis care in resource-limited settings.
- 4 December 2025
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(88),p. 39-44
Open AccessProspective case series on home-based handgrip resistance training with WhatsApp monitoring in patients with newly created arteriovenous fistulas
Successful maturation of arteriovenous fistulas (AVFs) remains a challenge for patients with end-stage kidney disease, particularly in resource-limited settings. Handgrip resistance training may enhance vascular hemodynamics and support AVF maturation. This prospective uncontrolled case series evaluated the feasibility, safety, and vascular changes of a four-week home-based handgrip program in patients with new AVFs. Methods. Twenty-eight adults with recent radiocephalic AVF creation performed daily handgrip training for four weeks (three sets of 10 contractions, 10 seconds each with 2-second rests; ~3–5 minutes/day). Adherence was tracked via logbooks and weekly WhatsApp submissions. Feasibility outcomes included adherence, completion, safety, and patient acceptability. Hemodynamic parameters (vein diameter, vein depth, and blood flow volume) were measured using Doppler ultrasonography before and after the intervention. Results. Of 28 participants, 23 (82.1%) completed the program with high adherence (≥85% sessions). No AVF-related adverse events occurred. Significant vascular changes were observed: vein diameter increased from 3.1 ± 0.4 mm to 5.5 ± 0.6 mm (p < 0.001), vein depth decreased from 2.5 ± 0.3 mm to 2.1 ± 0.4 mm (p = 0.002), and blood-flow volume increased from 180 ± 55 mL/min to 565 ± 110 mL/min (p < 0.001). Conclusions. Home-based handgrip training with digital monitoring is feasible, safe, and well accepted in patients with new AVFs. The observed vascular changes suggest this low-cost intervention may support AVF maturation and is suitable for integration into dialysis care in resource-limited settings.
- Open Access
- 25 June 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (2) , 75-80
Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
Background. Anthracycline chemotherapy is a cornerstone of cancer treatment but poses a risk of cardiotoxicity, often presenting as cancer therapy–related cardiac dysfunction (CTRCD). Monitoring left ventricular ejection fraction (LVEF) is essential to detect early cardiac impairment and support safer treatment strategies. Aim. To assess LVEF changes after six cycles of anthracycline therapy and identify predictive factors associated with CTRCD. Materials and methods. This observational pre–post study included 74 patients treated with anthracyclines at Dr. Wahidin Sudirohusodo Hospital, Makassar, from 2024 to 2025. LVEF was measured via echocardiographic surveillance before and after treatment. Cardiotoxicity was defined as a ≥10 % decrease in LVEF to ≤50 %. Statistical tools included Wilcoxon signed-rank test, Chi-square, ROC curve analysis, and logistic regression. Results. The mean LVEF significantly declined from 63.08 % to 56.76 % (p = 0.001). CTRCD occurred in 20.3 % of patients. Risk factors independently associated with cardiotoxicity included age ≥51 years (OR 2.80; p = 0.016) and cumulative anthracycline dose ≥457.5 mg/m² (OR 3.25; p = 0.004). When both factors were present, the risk increased nearly sixfold (OR 5.75; p = 0.001). Conclusions. CTRCD was observed in one-fifth of patients following anthracycline therapy, with age and dose being significant contributors. These findings support the integration of risk-based echocardiographic surveillance into oncology care to ensure early detection and mitigate long-term cardiac complications.
- 25 June 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (2) , 75-80
Open AccessEjection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
Background. Anthracycline chemotherapy is a cornerstone of cancer treatment but poses a risk of cardiotoxicity, often presenting as cancer therapy–related cardiac dysfunction (CTRCD). Monitoring left ventricular ejection fraction (LVEF) is essential to detect early cardiac impairment and support safer treatment strategies. Aim. To assess LVEF changes after six cycles of anthracycline therapy and identify predictive factors associated with CTRCD. Materials and methods. This observational pre–post study included 74 patients treated with anthracyclines at Dr. Wahidin Sudirohusodo Hospital, Makassar, from 2024 to 2025. LVEF was measured via echocardiographic surveillance before and after treatment. Cardiotoxicity was defined as a ≥10 % decrease in LVEF to ≤50 %. Statistical tools included Wilcoxon signed-rank test, Chi-square, ROC curve analysis, and logistic regression. Results. The mean LVEF significantly declined from 63.08 % to 56.76 % (p = 0.001). CTRCD occurred in 20.3 % of patients. Risk factors independently associated with cardiotoxicity included age ≥51 years (OR 2.80; p = 0.016) and cumulative anthracycline dose ≥457.5 mg/m² (OR 3.25; p = 0.004). When both factors were present, the risk increased nearly sixfold (OR 5.75; p = 0.001). Conclusions. CTRCD was observed in one-fifth of patients following anthracycline therapy, with age and dose being significant contributors. These findings support the integration of risk-based echocardiographic surveillance into oncology care to ensure early detection and mitigate long-term cardiac complications.